Resmed Inc
RMDFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Resmed Inc Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Resmed Inc — 10-K filed Aug 13, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 18 annual periods. The latest annual period ends Jun 30, 2026. The latest insider filing shown is dated Jun 9, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| ARCADIA INVESTMENT MANAGEMENT CORP/MI | 2026-03-31 | 500 | $112K | SEC filing |
| FLPUTNAM INVESTMENT MANAGEMENT CO | 2026-03-31 | 5,546 | $1.24M | SEC filing |
| Advisors Asset Management, Inc. | 2026-03-31 | 7,107 | $1.6M | SEC filing |
| United Community Bank | 2026-03-31 | 3 | $673 | SEC filing |
| Grove Bank & Trust | 2026-03-31 | 96 | $21.6K | SEC filing |
| Signature Resources Capital Management, LLC | 2026-03-31 | 7 | $1.57K | SEC filing |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2026-03-31 | 472,619 | Not shown | SEC filing |
| TRUST CO OF TOLEDO NA /OH/ | 2026-03-31 | 2 | $449 | SEC filing |
| Torren Management, LLC | 2026-03-31 | 5 | $1.14K | SEC filing |
| CARY STREET PARTNERS FINANCIAL LLC | 2026-03-31 | 15 | $3.37K | SEC filing |
| PNC FINANCIAL SERVICES GROUP, INC. | 2026-03-31 | 90,238 | $20.3M | SEC filing |
| Dai-ichi Life Insurance Company, Ltd | 2026-03-31 | 3,755 | $843K | SEC filing |
| Caitong International Asset Management Co., Ltd | 2026-03-31 | 4 | $898 | SEC filing |
| MV CAPITAL MANAGEMENT, INC. | 2026-03-31 | 215 | $48.3K | SEC filing |
| Bruce G. Allen Investments, LLC | 2026-03-31 | 38 | $8.53K | SEC filing |
| Engineers Gate Manager LP | 2026-03-31 | 4,572 | $1.03M | SEC filing |
| North Star Investment Management Corp. | 2026-03-31 | 13 | $2.92K | SEC filing |
| BRASADA CAPITAL MANAGEMENT, LP | 2026-03-31 | 18,437 | $4.15M | SEC filing |
| FEDERATED HERMES, INC. | 2026-03-31 | 6,041 | $1.36M | SEC filing |
| SANDERS MORRIS HARRIS LLC | 2026-03-31 | 4,600 | $1.03M | SEC filing |
- Each value is checked against Resmed Inc's share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Resmed Inc's share price.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Resmed Inc's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-11-07 · Farrell Michael J.: Larger than 61 of the 67 other insider sales of ResMed Common Stock on file. SEC filing
- 2025-08-18 · Hernandez John: Larger than all 14 other insider sales of ResMed Common Stock on file. SEC filing
- 2025-03-10 · Ghoshal Kaushik: Larger than 62 of the 67 other insider sales of ResMed Common Stock on file. SEC filing
- 2024-11-07 · Farrell Michael J.: Larger than 64 of the 67 other insider sales of ResMed Common Stock on file. SEC filing
- 2024-10-07 · Farrell Michael J.: Larger than 64 of the 67 other insider sales of ResMed Common Stock on file. SEC filing
- 2024-09-09 · Farrell Michael J.: Larger than 64 of the 67 other insider sales of ResMed Common Stock on file. SEC filing
- 2024-08-20 · Rider Michael J: Larger than 13 of the 14 other insider sales of ResMed Common Stock on file. SEC filing
- 2024-08-12 · Ghoshal Kaushik: Larger than 63 of the 67 other insider sales of ResMed Common Stock on file. SEC filing
- 2024-08-07 · Farrell Michael J.: Larger than 64 of the 67 other insider sales of ResMed Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-08 | Farrell Michael J. · Chairman and CEO | ResMed Common Stock | S — Open market or private sale | −4,991 | 193.96 | SEC filing |
| 2026-05-07 | Farrell Michael J. · Chairman and CEO | ResMed Common Stock | S — Open market or private sale | −4,991 | 207.82 | SEC filing |
| 2026-04-07 | Farrell Michael J. · Chairman and CEO | ResMed Common Stock | S — Open market or private sale | −4,991 | 225.50 | SEC filing |
| 2026-04-01 | FARRELL PETER C · Director | ResMed Common Stock | S — Open market or private sale | −2,000 | 225.00 | SEC filing |
| 2026-04-01 | Sandercock Brett · Chief Financial Officer | ResMed Common Stock | S — Open market or private sale | −1,000 | 224.31 | SEC filing |
| 2026-03-09 | Farrell Michael J. · Chairman and CEO | ResMed Common Stock | S — Open market or private sale | −4,991 | 251.03 | SEC filing |
| 2026-03-04 | FARRELL PETER C · Director | ResMed Common Stock | S — Open market or private sale | −2,000 | 260.22 | SEC filing |
| 2026-03-02 | Sandercock Brett · Chief Financial Officer | ResMed Common Stock | S — Open market or private sale | −1,000 | 254.30 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-08 | Farrell Michael J. · Chairman and CEO | ResMed Common Stock Options | M — Exercise or conversion of derivative security | −4,991 | SEC filing |
| 2026-06-08 | Farrell Michael J. · Chairman and CEO | ResMed Common Stock | M — Exercise or conversion of derivative security | +4,991 | SEC filing |
| 2026-06-01 | Rider Michael J · Global General Counsel | ResMed Common Stock | F — Payment of exercise price or tax by delivering securities | −269 | SEC filing |
| 2026-05-07 | Farrell Michael J. · Chairman and CEO | ResMed Common Stock Options | M — Exercise or conversion of derivative security | −4,991 | SEC filing |
| 2026-05-07 | Farrell Michael J. · Chairman and CEO | ResMed Common Stock | M — Exercise or conversion of derivative security | +4,991 | SEC filing |
| 2026-04-07 | Farrell Michael J. · Chairman and CEO | ResMed Common Stock | M — Exercise or conversion of derivative security | +4,991 | SEC filing |
| 2026-04-07 | Farrell Michael J. · Chairman and CEO | ResMed Common Stock Options | M — Exercise or conversion of derivative security | −4,991 | SEC filing |
| 2026-03-09 | Farrell Michael J. · Chairman and CEO | ResMed Common Stock | M — Exercise or conversion of derivative security | +4,991 | SEC filing |
Showing 8 of 33 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2024-10-30 | Ghoshal Kaushik · Chief Commercial Officer, SaaS | ResMed Common Stock | J — Other acquisition or disposition | +9,628 | SEC filing |
| 2024-10-30 | Ghoshal Kaushik · Chief Commercial Officer, SaaS | ResMed Common Stock | J — Other acquisition or disposition | −9,628 | SEC filing |
Showing 2 of 2 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.